R&D channel feed – Endpoints News

R&D channel feed

Novo's semaglutide handily whips Eli Lilly's Trulicity in a PhIII diabetes showdown

8 years ago

Bristol-Myers shares sink after another setback for its immuno-oncology franchise drugs

8 years ago

Drug developers face increasingly risky tightrope walk between top-line results and hard data

8 years ago

With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug

8 years ago

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

8 years ago

Zynerba shares crushed (again) as back-to-back flops leave lead drug under a cloud

8 years ago

Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII

8 years ago

Here's why Sucampo paid $200M for its PhIII Niemann-Pick drug

8 years ago

Gushing red ink, biotech billionaire Soon-Shiong slashes staff at NantHealth by 300, sells assets

8 years ago

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

8 years ago

Galapagos spotlights an 'exciting' round of PoC data for IPF drug, shares surge

8 years ago

Trying to turn a new leaf, Valeant ‘blockbuster’ can’t shed an R&D jinx

8 years ago

Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review

8 years ago

Sanofi believes it’s still not too late to become a top player in cancer drug market

8 years ago

Esperion shares bounce up on an effective triplet approach to slashing LDL

8 years ago

Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review

8 years ago

FibroGen shares rocket up on positive PhII data in idiopathic pulmonary fibrosis

8 years ago

Zynerba goes into meltdown mode as cannabis-derived drug flops in PhII

8 years ago

A small, groundbreaking cardio study pushes MyoKardia to a pivotal showdown — shares soar

8 years ago

GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons

8 years ago

Gemphire shares crater after its LDL drug comes up short in PhIIb

8 years ago

Eli Lilly’s new, $1B pain drug racks up another promising round of PhIII pain data

8 years ago

Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan

8 years ago

Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal

8 years ago

First page Previous page 293 294 295296297 298 299 Next page Last page